AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

How Important Is Ai in Improving Pharmacovigilance? | Quantzig Offers Expert Insights

November 29, 2019

LONDON--(BUSINESS WIRE)--Nov 29, 2019--

Quantzig, a global data analytics and advisory firm, that delivers actionable analytics solutions to resolve complex business problems announces the completion of their recent article that offers comprehensive insights on the ’ Role of AI in Improving Pharmacovigilance.’

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191129005119/en/

Pharmacovigilance companies face increasing pressures to improve their analytics capabilities and offer value-added services throughout the drug development lifecycle. Facing similar challenges? Request a FREE proposal to learn how we can help.

One of the key drivers for the growing demand for pharmacovigilance, the associated tools, and software can be attributed to a greater emphasis on drug safety and the drug manufacturing process. With the focus on all the major drug regulations being on improving the drug quality and prevention of drug-related problems, pharma companies are increasingly becoming dependent on tools to enhance drug safety. Consequently, a major pain point that most pharma companies face today revolves around the execution of foolproof digital vigilance on the data generated.

Leading pharmacovigilance companies use advanced analytics techniques for analysis of data including data mining, text mining, and data visualization. For more detailed information on such analytical methodologies and tools, talk to our analytics experts right away!

Role of AI in Enhancing Pharmacovigilance

Real-time Monitoring

Improved Drug Safety

The whole point of adopting pharmacovigilance is to monitor the drug development process. AI-based web monitoring is better than human supervised ones as its preloaded algorithm also makes it easier for pharma firms to track and analyze datasets from various sources.

AI plays a crucial role in deciphering human semantics, which in turn is essential for enhancing drug safety by monitoring drug development. By filtering out the irrelevant data and taking the subtext of the data into consideration, AI helps you conduct a focused analysis of drug use and patient requirement.

We can help you use analytics to improve drug development and enhance process efficiency. Wonder how? Schedule a FREE solution demo to get a glimpse of our analytics capabilities.

According to the analytics experts at Quantzig,“The biggest challenges faced by pharmacovigilance companies are the rising complexities associated with drug development, lack of new technology, rising costs, and a shortage of well-defined metrics.”

Request for more information ( http://bit.ly/33ru7oW ) to gain access to the latest analytics case studies, white papers, and reports in your industry!

About Quantzig

Quantzig is a global analytics and advisory firm with offices in the US, UK, Canada, China, and India. For more than 15 years, we have assisted our clients across the globe with end-to-end data modeling capabilities to leverage analytics for prudent decision making. Today, our firm consists of 120+ clients, including 45 Fortune 500 companies. For more information on our engagement policies and pricing plans, visit: https://www.quantzig.com/request-for-proposal.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191129005119/en/

CONTACT: Press

Quantzig

Anirban Choudhury

Marketing Manager

US: +1 630 538 7144

UK: +44 208 629 1455

https://www.quantzig.com/contact-us

KEYWORD: EUROPE UNITED STATES UNITED KINGDOM NORTH AMERICA

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH CONSULTING DATA MANAGEMENT PROFESSIONAL SERVICES TECHNOLOGY CLINICAL TRIALS

SOURCE: Quantzig

Copyright Business Wire 2019.

PUB: 11/29/2019 08:30 AM/DISC: 11/29/2019 08:30 AM

http://www.businesswire.com/news/home/20191129005119/en